Skip to content

Public FDA record

Z-0149-2027: Generic Name: FilmArray Pneumonia Panel plus Generic Name: FilmArray Pneumonia Panel plus Model/Catalog N

Recall record Z-0149-2027 for BioFire Diagnostics, LLC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0149-2027
Company in FDA record
BioFire Diagnostics, LLC
FDA classification date
Oct 13, 2026
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Due to potential contaiminated of spefic lots of pneumonia and joint infection panels that could result in false positive results

Source facts

Action
On 09/03/2026, an "URGENT: MEDICAL DEVICE RECALL (CORRECTION)" Letter was emailed to customers informing them that, bioMrieux internally identified increased rates of KPC unexpected positives in Quality Control (QC) testing of the BIOFIRE FILMARRAY PN Panel, BIOFIRE FILMARRAY PNplus Panel, and BIOFIRE JI Panel. Internal testing reproduced KPC unexpected positive results, suggesting KPC nucleic acid contamination in reagent manufacturing at levels that can lead to false positive results. Customers are instructed to: " Examine inventory for the lots identified in this recall. " If a positive KPC result obtained when using the affected product is inconsistent with local resistance epidemiology and clinical data, then the result should be confirmed with an alternative method. " If customer has further distributed or transferred this product to another facility, identify any recipients, notify them at once, and forward this notice. " Post the recall (correction) letter on or near affected products as a constant reminder of the actions that need to be taken. " Complete the accompanying Acknowledgement of Receipt Form and return to bioMrieux so that bioMrieux may acknowledge your receipt of this notification. For questions - contact your local Customer Service Representative at 1-800-682-2666, selecting option 1 for Technical Support and option 3 for BIOFIRE, or email biofiresupport@biomerieux.com
Initiated
2026-08-12
Root cause
Under Investigation by firm
Distribution
Worldwide - U.S. Nationwide distribution including in the states and territory of AK, AL, AR, AZ, CA, CO, CT, DC, FL, GA, GU, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, MT, NC, ND, NE, NJ, NM, NV, NY, OH, OK, OR, PA, PR, SC, SD, TN, TX, UT, VA, WA, WI, WV, and WY. The countries of United Arab Emirates, Netherland Antilles, Argentina, Austria, Bosnia and Herzegovina, Belgium, Bulgaria, Bolivia, Canada, Switzerland, Chile, China, Colombia, Costa Rica, Czech Republic, Germany, Denmark, Dominican Republic, Algeria, Ecuador, Spain, Finland, France, United Kingdom, Greece, Guatemala, Hong Kong, Honduras, Croatia, Hungary, Indonesia, Israel, India, Italy, Japan, Korea, Lebanon, Sri Lanka, Lithuania, Mexico, Malaysia, Nicaragua, Panama, Peru, Philippines, Poland, Portugal, Paraguay, Romania, Serbia, Singapore, El Salvador, Thailand, Taiwan, Venezuela, Vietnam.
Recall number
Z-0149-2027
Recall status
Open, Classified
CDRH record ID
221922
FDA classified
2026-10-13
Recall event number
99592

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗